Britain's weight loss drug boom reshapes eating habits and spending

The use of weight loss drugs such as Ozempic, Wegovy, and Mounjaro has risen sharply across Great Britain. A new report shows 6.3% of households now include at least one current user. This marks a steep increase from 4.1% in 2025 and just 2.3% in 2024. Around 1.9 million adults are currently taking these medications, nearly triple the number from two years ago. Women make up 77% of users, with 26% saying they would take GLP-1 drugs even without a major health concern.

The primary reason for use is weight loss, with 68% of users taking the medication for this purpose. Many report positive changes in their eating habits. Over half say they experience fewer cravings and less intrusive thoughts about food. A similar number describe their eating as more mindful.

User households have also adjusted their spending. They now buy more mouthwash and chewing gum. However, they spend £418 less overall than non-user households. Three-quarters of users have reduced their chocolate intake, while 72% cut back on crisps.

Cost remains a barrier for some. About 41% of users have stopped taking the medication because of its high price. The rapid growth in weight loss drug use reflects changing habits and priorities. User households spend less on certain foods and more on oral care products. Despite the benefits, the expense continues to deter some from continuing treatment.